Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1.
Ontology highlight
ABSTRACT: Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demons
SUBMITTER: Skansberg A
PROVIDER: S-EPMC8018392 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA